Asceneuron
With over 20 years of experience in intellectual property for the pharmaceutical and chemical industry, Colin provides essential input to Asceneuron's strategy to protect its small molecule pipeline assets and supports the company in the management of its intellectual property portfolio.
This person is not in any teams
This person is not in any offices
Asceneuron
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.